LONDON—Strikingly successful treatment results were reported in patients with myelofibrosis — a disabling, disfiguring and fatal cancer, for which no therapy has been available up to now — at the Euro
Srdan Verstovsec
LONDON—Strikingly successful treatment results were reported in patients with myelofibrosis — a disabling, disfiguring and fatal cancer, for which no therapy has been available up to now — at the European Haematology Association annual meeting held in London (June 8-12, 2011). Srdan Verstovsek from the MD Anderson Cancer Center in Texas tells the audio journal of oncology about his group’s data from a placebo-controlled study investigating treatment with the monoclonal antibody ruxolitinib which inhibits the JAK II enzyme. Organomegaly was reversed and symptoms reduced in the COMFORT I and COMFORT II studies.
More news from the EHA congress at http://www.ecancermedicalscience.com.
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/110613SrdanVerstovsekPODCASTLoRes.mp3]